Immuneering (IMRX) SEC Filings

Immuneering Corporation (IMRX) reported third-quarter results and clinical-program updates. The company said follow-up in its Phase 2 first-line pancreatic cancer trial is being extended because patients are living longer than projected. Updated data from the atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) arm, which includes 55 patients, are expected in the first half of 2027. Enrollment in Phase 3 MAPKeeper 301 is ahead of schedule; the company is expanding the target from 510 to approximately 570 patients and says this could potentially accelerate its current mid-2028 topline data guidance.

Cash, cash equivalents and marketable securities were $166.1 million as of September 30, 2026, compared with $217.0 million as of December 31, 2025. Third-quarter net loss attributable to common stockholders was $24.2 million, compared with $15.0 million a year earlier. Research and development expenses were $20.7 million versus $10.9 million, and general and administrative expenses were $5.1 million versus $4.5 million. Management expects the cash runway to fund operations into the fourth quarter of 2028, based on quarter-end funds and current operating plans.

Immuneering Corporation is a late-stage clinical oncology company advancing Deep Cyclic Inhibitor therapies, led by atebimetinib (IMM-1-104), an oral MEK inhibitor. A global Phase 3 registrational trial, MAPKeeper 301, began dosing first-line metastatic pancreatic cancer patients in June 2026, targeting about 510 patients with overall survival as the primary endpoint.

For the six months ended June 30, 2026, Immuneering reported a net loss of $30.7 million, compared with $29.5 million a year earlier, driven by $24.6 million in research and development and $9.7 million in general and administrative expenses. Net loss per share was $0.48. Cash used in operating activities was $34.9 million.

As of June 30, 2026, the company held approximately $182.7 million in cash, cash equivalents and marketable securities, total assets of $202.1 million, and stockholders’ equity of $190.7 million. Management states this liquidity is expected to fund operations, including ongoing trials, into 2029.

Immuneering Corporation reported second-quarter 2026 results and progress across its oncology pipeline. In a single-arm Phase 2a study in first-line pancreatic cancer, atebimetinib plus modified gemcitabine/nab-paclitaxel showed a 17.3 month median overall survival in 55 patients, with 84% of evaluable patients weight stable or gaining at three months and limited high-grade treatment-related adverse events. A pivotal global Phase 3 MAPKeeper 301 trial in first-line metastatic pancreatic cancer is now dosing patients at more than 30 sites, supported by new peer-reviewed data in Cancer Research describing atebimetinib’s mechanism and preclinical activity.

Cash, cash equivalents and marketable securities totaled $182.7 million as of June 30, 2026, and the company expects its cash runway to extend into 2029. Second-quarter R&D expenses were $14.0 million and G&A expenses were $5.0 million. Net loss attributable to common stockholders was $17.3 million, or $0.27 per share. The company also appointed Andrew Gengos as Chief Financial Officer and outlined additional trials and preclinical milestones through 2028.

Immuneering Corp reported that BlackRock, Inc., a Delaware corporation, beneficially owns 4,356,235 shares of Immuneering’s Class A stock, representing 6.7% of the class as of June 30, 2026. BlackRock has sole voting power over 4,314,766 shares and sole dispositive power over 4,356,235 shares, with no shared voting or dispositive power.

Various underlying clients and other persons have rights to dividends or sale proceeds related to these shares, but no individual person holds more than 5% of Immuneering’s outstanding common shares through these interests.

Immuneering Corp granted Chief Financial Officer Andrew Gengos stock options covering 650,000 shares of Class A Common Stock at an exercise price of $4.78 per share, expiring July 16, 2036. The options vest monthly over four years under a detailed, step-up vesting schedule tied to continued employment.

Immuneering Corp executive Andrew Gengos, Chief Financial Officer, reports ownership of 225,000 shares of Class A Common Stock, held directly. This disclosure outlines his reported equity stake as an officer and does not list any open-market transactions or derivative positions.

Immuneering Corp director and CEO Benjamin J. Zeskind reported buying 2,400 shares of Class A Common Stock in an open-market purchase on June 23, 2026 at a weighted average price of $4.5617 per share, with individual trade prices ranging from $4.55 to $4.59 through a broker-dealer.

After this transaction, he directly owns 2,315,252 shares of Immuneering’s Class A Common Stock. A separate entry shows 894,927 shares held indirectly by the Benjamin J. Zeskind 2020 Family Trust, where his spouse Lisa Schwartz serves as sole trustee.

Immuneering Corp's Chief Scientific Officer Brett Matthew Hall reported an open-market purchase of Class A Common Stock. On June 15, 2026, he bought 6,035 shares at a weighted average price of $4.15 per share. Following this transaction, he directly owns 382,531 shares of Immuneering Corp stock. The filing notes the trade was executed through a broker-dealer in multiple transactions at prices ranging from $4.146 to $4.15 per share, with the reported price representing the weighted average.

Immuneering Corporation is appointing Andrew Gengos as Chief Financial Officer, Treasurer and principal financial officer, effective when he starts work, expected on or before July 16, 2026. Current Senior Vice President Finance and Chief Accounting Officer Mallory Morales will remain the company’s principal accounting officer.

Gengos will receive an annual base salary of $530,000 and be eligible for a target annual bonus equal to 40% of base salary, based on Board-set objectives. As a material inducement to join, he is expected to receive an option to purchase 650,000 shares of common stock under the 2025 Employment Inducement Award Plan, contingent on his start date.

If terminated without cause or he resigns for good reason, he is eligible for 12 months of base salary continuation, any earned prior-year bonus, and up to 12 months of subsidized COBRA. After a qualifying change in control, he may instead receive similar salary and COBRA benefits, an additional payment equal to 1.0x his target bonus, and accelerated vesting of specified equity awards.